Roche and MedImmune will concoct lung cancer immunotherapy clinical trial test

Roche's ($RHHBY) Ventana Medical Systems and MedImmune said they will jointly develop an assay to help test a MedImmune immunotherapy for non-small cell lung cancer. Neither side is disclosing financial details. Specifically, they'll develop a PD-L1 (SP263) immunohistochemistry assay to enroll patients in clinical trials for MedImmune's MEDI4736, an anti-PD-L1 therapy. According to the companies, signals from PD-L1 help tumors avoid immune system detection. The idea is that MedImmune's treatment could combat this by targeting PD-L1, and Roche/Ventana will develop a test that screens for patients who may benefit most from the cancer immunotherapy. Release

Suggested Articles

Johnson & Johnson Vision announced that the worldwide president of its surgical business, Tom Frinzi, plans to retire at the end of this year.

Philips looked back on 15 years of data from one of its telehealth-equipped intensive care units, where centralizing operations reduced mortality.

Sanofi will look to pull back from its three-year-old relationship with Verily and their virtual diabetes clinic, Onduo.